What are the appropriate dosage, administration instructions, contraindications, and precautions for benzonatate in an adult patient?

Benzonatate Dosing and Administration

For adult patients, benzonatate should be dosed at 100-200 mg three times daily (up to 600 mg maximum daily), with capsules swallowed whole—never chewed, crushed, or dissolved—due to risk of oral anesthesia and choking. 1

Dosage

• Standard dose: 100-200 mg three times daily as needed for cough
• Maximum daily dose: 600 mg in three divided doses
• Frequency: Every 8 hours (three times daily)
• Not approved for children under 10 years of age 1

Critical Administration Instructions

Capsules must be swallowed whole. Breaking, chewing, dissolving, cutting, or crushing benzonatate capsules releases the medication in the mouth, causing:

• Temporary local anesthesia of oral mucosa
• Numbness/tingling of tongue, mouth, throat, or face
• Choking risk
• If oral numbness occurs, avoid eating or drinking until sensation returns 1

Contraindications and Precautions

High-Risk Populations

Children under 10 years: Benzonatate is contraindicated due to multiple reported fatalities from accidental ingestion. Death has occurred within 15-20 minutes of ingestion in young children, with fatal outcomes reported within one hour 1, 2, 3.

Pregnancy (Category C): Use only if clearly needed; no adequate human studies exist 1

Nursing mothers: Unknown if excreted in breast milk; use with caution 1

Chemical Sensitivity Warning

Benzonatate is structurally related to para-aminobenzoic acid (PABA) anesthetics (procaine, tetracaine). Patients with prior sensitivity to these agents may experience adverse CNS effects 1.

Clinical Positioning

According to CHEST guidelines, benzonatate is reserved as a fourth-line agent for refractory cough:

1. First-line: Demulcents (simple linctus, glycerol-based syrups)
2. Second-line: Opioid derivatives (codeine, morphine)
3. Third-line: Peripherally-acting antitussives (levodropropizine, sodium cromoglycate)
4. Fourth-line: Local anesthetics including benzonatate 4

The guideline specifically recommends benzonatate for "opioid-resistant cough that does not respond to peripheral antitussives" 4.

Safety Concerns

Overdose Risk

Serious toxicity occurs rapidly with overdose, particularly concerning given:

• Fatal outcomes reported in adults with ingestion of <30 capsules (6000 mg) 5
• Symptoms develop within 15-20 minutes: restlessness, tremors, seizures, cardiac arrest, coma 1, 6
• Intentional exposures carry 22% risk of serious adverse effects (seizures, dysrhythmias, death) 7
• Two deaths occurred in a 20-year poison center review 7

Storage and Dispensing

Keep out of reach of children. Accidental pediatric ingestion has resulted in multiple fatalities. Pharmacists should counsel caregivers on:

• Safe storage practices
• Recognition of overdose symptoms
• Need for immediate emergency care if ingestion suspected 2

Missed Dose

If a dose is missed, skip it and resume at the next scheduled time. Never double dose 1.

Common Pitfalls

1. Chewing capsules: Patients may not understand the severity of this warning. Emphasize that oral anesthesia can cause aspiration
2. Pediatric prescribing: Despite FDA approval for ages ≥10 years, the risk-benefit ratio is questionable given limited efficacy data and overdose risk
3. First-line use: Benzonatate should not be initial therapy; reserve for refractory cases after safer options fail
4. Inadequate caregiver education: Many accidental pediatric exposures occur when medications are left accessible 3

Evidence Quality Note

The evidence supporting benzonatate efficacy is remarkably weak. A 2023 systematic review found that approval was based on very small studies with high bias that "would not stand up to current regulatory review" 8. Most safety data comes from overdose case reports rather than controlled trials. The CHEST guideline recommendation is consensus-based (ungraded) rather than evidence-based 4.